Immerse yourself in CGT policy discussions at the Policy Summit, Sept. 18-19!
Learn more about sessions and presentations at the 26th Annual Meeting
Friday, May 19 2023 8:00 AM – 9:45 AM PT
An array of exciting new cell- and gene-based approaches are being developed for therapeutic discovery and potential treatment of heart and blood vessel diseases. This session will profile four examples of such emerging technologies: 1) gene editing to correct vascular smooth muscle dysfunction, 2) gene therapy to enhance the contractility of failing hearts, 3) gene therapy to promote myocardial regeneration via reactivation of cardiomyocyte proliferation, and 4) viral vectors engineered to enable selective targeting of specific (e.g., cerebral) blood vessel types.
8:00 AM – 9:45 AM - Room 411
Jeffrey L.. Ellsworth, PhD. Stellar Research and Development, LLC, MA
Michael A. Laflamme, MD, PhD. McEwen Stem Cell Institute, University Health Network, University of T...
8:01 AM – 8:25 AM - Room 411
Mark E. Lindsay, MD, PhD. Massachusetts General Hospital, Boston, MA
8:25 AM – 8:50 AM - Room 411
Catherine Makarewich, PhD. Cincinnati Children's Hospital Medical Center, OH
8:50 AM – 9:15 AM - Room 411
Mauro Giacca, PhD, MD. King's College London, United Kingdom
9:15 AM – 9:40 AM - Room 411
Benjamin E.. Deverman, PhD. Broad Institute, Cambridge, MA
© 2000-2023 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico